click below
click below
Normal Size Small Size show me how
IOS8
Exam1 (seizure/pain meds)
| Question | Answer |
|---|---|
| MOA of vigabatrin | Enhance GABA levels by inhibiting GABA transaminase |
| MOA of Tiagabine | Blocks the reuptake of GABA |
| MOA of gabapentin | Accumulation & enhancement of GABA release; binds to alpha-2-delta subunit of voltage-sensitive L-type Ca channels to reduce inward Ca current |
| MOA of pregabalin | Accumulation & enhancement of GABA release; binds alpha-2-delta subunit of voltage-gated Ca channel, modulating the release of glutamate, NE, and substance P |
| MOA of Barbiturates | Enhance Cl conductance through GABA-A, thereby enhancing GABA |
| MOA of Benzodiazepines | Enhance Cl conductance through GABA-A, thereby enhancing GABA |
| MOA of topiramate | Enhance GABA; block Na channels; block L-type Ca channels; blocks Kainate glutamate receptors, weak carbonic anhydrase inhibitor |
| MOA of Felbamate | Enhance GABA; blocks NMDA receptors |
| MOA of Valproate | Enhance GABA; blocks Na channels; blocks T-type Ca channels in thalamus (absence) |
| MOA of phenytoin | blocks Na channels |
| MOA of Carbamazepine | blocks Na channels |
| MOA of lamotrigine | blocks Na channels; blocks glutamate release |
| MOA of Primidone | enhances GABA (like 3 drugs wrapped into one with phenobarbital being the most active) |
| MOA of oxcarbazepine | blocks Na channels |
| MOA of zonisamide | blocks Na channels; blocks T-type Ca channels in thalamus (absence), carbonic anhydrase inhibitor |
| MOA of lacosamide | Selective enhancement of Na channel; slow inactivation. Binds to CRMP-2. |
| MOA of levetiracetam | Enhances the function of SV2A that inhibits abnormal bursting in epileptic circuits. |
| Enzyme Induction | Phenobarbital, phenytoin, primidone, carbamazepine (autoinduction), felbamate, topiramate (above 200mg/day), oxcarbazepine (higher doses), vigabatrin |
| Enzyme inhibition | Valproic acid, felbamate, oxcarbazepine (mild), topiramate (mild), vigabatrin |
| AEDs with aromatic rings that can show cross-reactivity | Phenytoin, carbamazepine, phenobarbital, oxcarbazepine, lamotrigine (metabolite) |
| Causes of breakthrough seizures | Nonadherence, insomnia, emotional/physical stress |
| Monitoring AED therapy | LFTs, CBC, platelets, Chem 8, neurological exam and patient report, serum level (trough if short t1/2) |
| MOA of ethosuximide | Blocks T-type Ca channels in thalamus (absence) |
| MOA of phenobarbital | enhances GABA |
| Indications of Phenobarbital | GTCS, PS, SE |
| Indications of phenytoin | GTCS, PS, SE |
| Side Effects of Phenytoin | gingival hyperplasia, hirsutism |
| Indications of Primidone | GTCS, PS |
| Side effects of ethosuximide | hiccups, aggression, nightmares, GI upset |
| Indications of valproate | Broad spectrum, PS, GTCS, pain, migraine prophylaxis, bipolar, absence |
| Side effects of valproate | tremor, weight gain, hair thinning (less with ER), hepatotoxicity Increases conc. of lamotrigine (reduce dose by 50%) |
| Indications of carbamazepine | PS, GTCS, bipolar, pain, (can make absence worse) |
| Side effects of carbamazepine | visual distortion, SIADH, cardiac arrhythmias |
| Indications of felbamate | LGS, GTCS, PS Use only in patients that are unresponsive to other AEDs |
| Side effects of felbamate | insomnia, weight loss, aplastic anemia, liver failure, rash (SJS) |
| Indications of lamotrigine | LGS, GTS, PS, absence, myoclonic, bipolar Metabolized by the liver (glucuronidation) |
| Side effects of lamotrigine | visual distortion, weight neutral, Rash (titrate dose slowly to prevent SJS or TEN) Reduce dose by 50% with valproate Double dose with carbamazepine |
| Indications of gabapentin | PS (add-on), pain, post herpatic neuralgia |
| Side effects of gabapentin | edema, weight gain, thinking problems Renal elimination |
| Indications of topiramate | LGS, PS, GTCS, myoclonus, bipolar, migraine |
| Side effects of topiramate | paresthesias, weight loss (dose dependent), kidney stones (drink water), decreased cognition, acute myopia, and secondary glaucoma |
| Side effects of levetiracetam | somnolence, fatigue, incoordination, behavioral changes (monitor psychosis), dizziness |
| Clinical pearls of oxcarbazepine | Measure MHD plasma levels, monitor Na, dose at 1.2-1.5 times daily dose of CBZ |
| Metabolism of zonisamide | glucuronidation, kidney elimination, sulfonamide derivative |
| Side effects of zonisamide | kidney stones, weight loss, parasthesias |
| MOA of rufinamide | Prolongation of the inactive state of Na channels |